In the IMpassion 130 study that assessed the effic
Post# of 158054
(Total Views: 244)
Posted On: 10/19/2025 7:48:50 PM
In the IMpassion 130 study that assessed the efficacy of Atezolizumab (Tecentrig) (targets PD-L1), the PD-L1 positive patient subgroup exhibited prolonged overall survival and progression-free survival (12,31).
By contrast, the GepaNuevo clinical trial of another anti-PD-L1 agent reported that durvalumab did not induce differences in therapeutic efficacy according to PD-L1 status (13).
These studies suggest that the efficacy of ICIs according to the status of PD-L1 expression in cancer remains unclear.
In clinical trials, PD-L1 levels in immune cells and tumor cells have been used as the criterion for selecting patient groups (20).
Nevertheless, the efficacy of ICI therapy was not guaranteed in a number of patients with a high tumor PD-L1 exprssion levels (32-35).
By contrast, the GepaNuevo clinical trial of another anti-PD-L1 agent reported that durvalumab did not induce differences in therapeutic efficacy according to PD-L1 status (13).
These studies suggest that the efficacy of ICIs according to the status of PD-L1 expression in cancer remains unclear.
In clinical trials, PD-L1 levels in immune cells and tumor cells have been used as the criterion for selecting patient groups (20).
Nevertheless, the efficacy of ICI therapy was not guaranteed in a number of patients with a high tumor PD-L1 exprssion levels (32-35).
(4)
(0)